Skip to content

Bicara Therapeutics BCAX Balance Sheet Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$323.46M-30.0%$96.69M-80.3%$171.67M-67.0%$436.61M+114%$462.07M
$544.92M$422.05M$297.37M$444.39M
$346K$330K$135K$117K
$553.6M$430.99M$424.69M$453.59M
$39.34M$28.95M$21.03M$17.23M
$39.64M$29.54M$21.91M$18.39M
500M500M500M500M
-$415.18M-$358.97M-$321.58M-$285.25M
$513.96M+12.0%$401.45M-18.4%$402.78M-21.0%$435.2M+349%$458.96M+387%
$553.6M$430.99M$424.69M$453.59M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Bicara Therapeutics's total assets?
Bicara Therapeutics (BCAX) holds $553.6M in total assets, up 15.8% year over year.
How much debt does Bicara Therapeutics have?
Bicara Therapeutics carries $1.4M in total debt against $514.0M of shareholders' equity, a debt-to-equity ratio of 0.00.
How much cash does Bicara Therapeutics have?
Bicara Therapeutics holds $323.5M in cash and equivalents.
Can Bicara Therapeutics cover its short-term obligations?
Its current ratio is 13.85 — current assets exceed current liabilities.
Where does Bicara Therapeutics's balance sheet data come from?
Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.